MiniMed 780G System for Type 1 Diabetes

Recruiting at21 trial locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Medtronic Diabetes

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests a new insulin (Lyumjev®) with an advanced insulin pump (MiniMed™ 780G) in people aged 7-80 with type 1 diabetes. The pump helps control blood sugar by adjusting insulin delivery automatically. The MiniMed™ 780G is a second-generation advanced system designed to improve blood sugar control in people with type 1 diabetes.

Research Team

Eligibility Criteria

Inclusion Criteria

7-13 years of age: A clinical diagnosis of type 1 diabetes for 1 year or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.

2-6 years of age: A clinical diagnosis of type 1 diabetes for 6 months or more, as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis

You are willing to participate in the study.

Exclusion Criteria

Is a member of the research staff involved with the study

Your hematocrit level is lower than the normal range.

You are currently receiving dialysis treatment.

Treatment Details

Interventions

• Lyumjev® lispro-aabc (Insulin)
• MiniMed 780G System (Device)

Participant Groups

Group I: MiniMed 780G System Utilizing Insulin Lyumjev® Experimental Treatment 1 Intervention

Subjects with insulin-requiring type 1 diabetes age 7-80 using the MiniMed 780G system with Insulin Lyumjev® for a period of three months.

Who Is Running the Clinical Trial?

Medtronic Diabetes

Lead Sponsor

Trials

73

Recruited

11,800+

Geoff Martha

Medtronic Diabetes

Chief Executive Officer since 2020

Finance degree from Penn State University

Dr. Kweli Thompson

Medtronic Diabetes

Chief Medical Officer since 2022

MD from Harvard Medical School

Eli Lilly and Company

Industry Sponsor

Trials

2,708

Recruited

3,720,000+

Dr. Daniel Skovronsky

Eli Lilly and Company

Chief Medical Officer since 2018

MD from Harvard Medical School

David A. Ricks

Eli Lilly and Company

Chief Executive Officer since 2017

BSc from Purdue University, MBA from Indiana University